Epilepsy in patients with multiple sclerosis: specific features of diagnosis and therapy
https://doi.org/10.14412/2074-2711-2015-1S-41-46
Abstract
Once the symptoms of multiple sclerosis (MS) occur, the risk of developing epilepsy within 5 years is 1.1%; this indicator doubles and triples 10 and 15 years after MS.
Objective: to specify the epidemiology of MS in the Moscow Region and management tactics for patients with MS and epileptic seizures (ES).
Patients and methods. Out of 906 patients diagnosed with MS, 9 (0.99%) (4 men and 5 women; mean age 28.62±4.59 years) were observed to have ES. The annual MS exacerbation rate was 1.2±1.19. Two MS patients were untreated for MS; 7 took MS-modifying drugs: interferonβ1a (n=2) or glatiramer acetate (n=5). The course of epilepsy and MS was retrospectively assessed. Two patient groups were identified: the first diagnosis was epilepsy (Group 1) and MS (Group 2). The patients were followed up jointly by a MS center physician and an epileptologist. If they had any indications, the patients underwent brain contrast-enhanced magnetic resonance imaging (MRI) (at least 1.5 T) and electroencephalography (EEG), EDSS health assessment, antiepileptic therapy (AET) analysis and correction.
Results. The incidence rate of ES in MS patients is about 1%, which is 2.5 times greater than that for the adult population in the Moscow Region. ESs are accompanied by secondary generalization in more than 60% of the cases; serial and status convulsive seizures are recorded in one third of the patients. More than half of ES cases are associated with MS exacerbations.
Conclusion. The use of AET after the first ESs is justified due to a high risk of recurrent seizures. Complete ES control can be achieved by AET as monotherapy in more than 70% of cases. If EP occurs, the patients with MS should undergo contrast-enhanced MRI of the brain to rule out an exacerbation.
About the Authors
Yu. A. Belova
M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia 61/2, Shchepkin St., Moscow 129110
Russian Federation
Russian Federation
T. I. Yaukushina
M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia 61/2, Shchepkin St., Moscow 129110
Russian Federation
Russian Federation
I. G. Rudakova
M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia 61/2, Shchepkin St., Moscow 129110
Russian Federation
Russian Federation
S. V. Kotov
M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow, Russia 61/2, Shchepkin St., Moscow 129110
Russian Federation
Russian Federation
References
1. Бойко АН, Гусев ЕИ. Современные подходы к лечению рассеянного склероза. Неврологический вестник им. В.М. Бехтерева. 2010; XLII(1):156–7. [Boyko AN, Gusev EI. Modern approaches to treatment of multiple sclerosis. Nevrologicheskiy vestnik im. V.M. Bekhtereva. 2010; XLII(1):156–7. (In Russ.)].
2. Пизова НВ. Эпилепсия у больных c рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;(4):84–7. [Pizova NV. Epilepsy at patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;(4):84–7. (In Russ.)].
3. Котов СВ, Якушина ТИ, Лиждвой ВЮ. Сравнительный анализ эффективности ПИТРС при ремиттирующем течении рассеянного склероза. В кн.: Материалы ХVIII всероссийской конференции «Нейроиммунология. Рассеянный склероз». Санкт-Петербург; 2011;9(3–4):91. [Kotov SV, Yakushina TI, Lizhdvoy VYu. The comparative analysis of efficiency of PITRS at the remittiruyushchy course of multiple sclerosis. In: Materialy XVIII vserossiyskoy konferentsii «Neyroimmunologiya. Rasseyannyy skleroz». [Materials XVIII of the All-Russian conference «Neuroimmunology. Multiple sclerosis»]. Saint-Petersburg; 2011; 9(3–4):91].
4. Котов СВ, Якушина ТИ, Лиждвой В.Ю. Длительное сравнительное исследование эффективности препаратов, изменяющих течение рассеянного склероза. Альманах клинической медицины. 2011;(25):37–40. [Kotov SV, Yakushina TI, Lizhdvoy VYu. Long comparative research of efficiency of the preparations changing the course of multiple sclerosis. Almanac of clinical medicine. 2011; (25):37–40. (In Russ.)].
5. Olafsson E, Benedikz J, Hauser WA. Risk of epilepsy in patients with multiple sclerosis: a population-based study in Iceland. Epilepsia. 1999 Jun;40(6):745–7.
6. Antiguedad A, Sanchez JL, Zaranz JJ. Secondary epilepsy in patients with multiple sclerosis. Neurologia. 1994;9(7):311–2.
7. Sokic DV, Stojsavljevic N, Drulovic J, et al. Seizures in multiple sclerosis. Epilepsia. 2001;42(1):72–9.
8. Moreau T, Sochurkova D, Lemesle M. Epilepsy in patients with multiple sclerosis: radiological-clinical correlations. Epilepsia. 1998;39(8):893–6.
9. Polman CH, Stephen CR, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the «McDonald» Criteria. Ann Neurol. 2005;(58):840–6.
10. Poser СМ, Brinar VV. Epilepsy and multiple sclerosis. Epilepsy Behav. 2003;4(1):6–12.
11. Завалишин ИА, Невская ОМ. Эпилептические приступы у пациентов с рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. 1984;84(6):868–71. [Zavalishin IA, Nevskaya OM. Epileptic attacks at patients with multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 1984; 84(6):868–71. (In Russ.)].
12. Jeffrey L, Sponsler MD, Kendrick-Adey AC. Seizure as a manifestation of multiple sclerosis: A case report and literature review. Epileptic Disord. 2011 Dec;13(4):401–10. DOI: 10.1684/epd.2011.0468.
13. Striano P, Striano S, Carrieri PB, Boccella P. Epilepsia partial continua as a first symptom of multiple sclerosis: electrophysiological study of one case. Mult Scler. 2003;9(2):199–203.
14. Nicoletti A, Sofia V, Biondi R, et al. Epilepsy and multiple sclerosis in Sicily: a population-based study. Epilepsia. 2003;44(11):1445–8.
15. Muller J, Templin A, Sauermann W. Epileptic seizures in multiple sclerosis. Psychiatr Neurol Med Psychol (Leipz). 1986;38(9):497–502.
16. Nyquist PA, Cascino GD, Rodriguez M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochestr, Minn, 1990–1998. Mayo Clin Proc. 2001 Oct;76(10):983–6.
17. Nyquist PA, Cascino GD, McClelland RL. Incidence of seizures in patients with multiple sclerosis: a population-based study. Mayo Clin Proc. 2002 Sep;77(9):910–2.
18. Okada S, Kinoshita M, Fujioka T, Yoshimura M. Two cases of multiple sclerosis with painful tonic seizures and dysesthesia ameliorated by the administration of mexiletine. Jpn J Med. 1991 Jul–Aug;30(4):373–5.
19. Belletrutti PJ, Courchesne CE, Gray GW. Seizure as the manifestation of relapse ofmultiple sclerosis in a military pilot. Aviat Space Environ Med. 2004; Apr;75(4):367–9.
20. Vyskocilova D, Vancurova R. Epileptic seizures as a first manifestation of multiple sclerosis. Abstracts from the 7 European Congress on Epileptology 2006;43.
21. Gurtubay IG, Gila L, Morales G, et al. Multiple sclerosis and epileptic seizures. Rev Neurol. 2000 May 1–15;30(9):827–32.
22. Truyen L, Barkhof F, Frequin ST, et al. Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. Mult Scler. 1996Feb;1(4):213–7.
23. Eriksson M, Ben-Menachem E, Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult Scler. 2002 Dec;8(6):495–9.
24. Gambardella A, Valentino P, Labate A, et al. Temporal lobe epilepsy as a unique manifestation of multiple sclerosis. Can J Neurol Sci. 2003 Aug;30(3):228–32.
25. Thompson AJ, Kermode AG, Moseley IF, et al. Seizures due to multiple sclerosis: seven patients with MRI correlations. J Neurol Neurosurg Psychiatry. 1993 Dec;56(12):1317–20.
26. Striano P, Orefice G, Morra BV, et al. Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurol Sci. 2003 Dec;24(5):322–8.
27. Bolay H, Ay H, Saygi S, Ciger A. Late onset absence seizures in multiple sclerosis: a case report. Clin Electroencephalogr. 1995 Apr;26(2):124–30.
28. Garcia-Asensio S, Lopez del Val J, Barrena R, et al. Epilepsy as the first sign of multiple sclerosis. Rev Neurol. 1997 Jan;25(137):80–3.
29. Kinnunen E, Wikströ m J. Prevalence and prognosis of epilepsy in patients with multiple sclerosis. Epilepsia. 1986 Nov–Dec;27(6):729–33.
30. Kharatishvili I, Pitkä nen A. Association of the severity of cortical damage with the occurrence of spontaneous seizures and hyperexcitability in an animal model of posttraumatic epilepsy. Epilepsy Res. 2010 Jun;90(1–2):47–59. DOI: 10.1016/j.eplepsyres.2010.03.007.
31. Котов АС, Белова ЮА. Эффективность лечения эпилепсии разными противоэпилептическими препаратами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(9):34–7. [Kotov AS, Belova YuA. Efficiency of treatment of epilepsy different antiepileptic preparations. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(9):34–7. (In Russ.)].
32. Рудакова ИГ, Котов СВ, Белова ЮА, Лаврентьева НС. Леветирацетам (Кеппра) в лечении различных эпилептических синдромов у взрослых. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;109(10):25–9. [Rudakova of IG, Kotov SV, Belov YuA, Lavrentyeva NS. Levetiratsetam (Keppra) in treatment of various epileptic syndromes at adults. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2009;109(10):25–9. (In Russ.)].
Review
For citations:
Belova Yu.A., Yaukushina T.I., Rudakova I.G., Kotov S.V. Epilepsy in patients with multiple sclerosis: specific features of diagnosis and therapy. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(1S):41-46. (In Russ.) https://doi.org/10.14412/2074-2711-2015-1S-41-46
Views: 2776
Email this article 